IPRs

Discussion Paper on IP and Access to Publicly Funded Research Results in Health Emergencies. Publicly Funded International R&D Projects

dlegge — Thu, 09 May 2024 01:19:26 +0000

Discussion Paper on IP and Access to Publicly Funded Research Results in Health Emergencies. Publicly Funded International R&D Projects

30 June 2023

dlegge Thu, 09/05/2024 - 11:19

Author/s

Yiqi Liu and Suerie Moon

WIP

Discussion Paper on IP and Access to Publicly Funded Research Results in Health…

During the COVID-19 pandemic, the public sector provided significant funding to accelerate the research and development (R&D) of health products. Globally, however, unequal and inequitable access to such products has prompted questions on how placing strategic conditions on public funding could improve access to the fruits of R&D. An important aspect of this issue is how conditions on intellectual property (IP) can contribute to achieving public policy goals such as affordable pricing and reliable supply. To facilitate the discussion, the present report provides empirical evidence of conditions adopted by publicly funded international R&D projects directed at health emergencies, with a particular focus on IP management.

A review of the literature found that public funding plays a central and critical role in R&D for health emergencies. However, governments have largely taken national rather than international approaches to such investments, prioritizing funding for research entities based in their own territories. Numerous expert bodies have called for conditions on public R&D funding to be strengthened, both for emergencies and for day-to-day R&D, but limited action has been taken to date.

We present five case studies of publicly funded international R&D projects, based on publiclyavailable information and interviews with key informants. For each project, we review and analyze the operational model, IP management approach and progress to date. To the extent possible, sample contractual provisions are included in Annex II for reference and further analysis.

More, much more

Keywords

IPRs

R&D for Health Products

A2M (Access to health technologies)

Emergencies

Swiss trade deal: Is India changing its tune on pharma patents?

dlegge — Wed, 28 Feb 2024 03:51:20 +0000

Swiss trade deal: Is India changing its tune on pharma patents?

27 February 2024

dlegge Wed, 28/02/2024 - 14:51

Author/s

Jessica Davis Pluss;' Pauline /Turuban

Swis Info

Swiss trade deal: Is India changing its tune on pharma patents?

Intellectual property protection for the Swiss pharmaceutical industry has been a key sticking point in negotiations on a free trade agreement with India. Now there seems to be a breakthrough in talks after 16 years. What’s changed?

Keywords

IPRs

IP PROTECTION IN A POST-PANDEMIC WORLD

dlegge — Sun, 21 Jan 2024 01:06:30 +0000

IP PROTECTION IN A POST-PANDEMIC WORLD

01 June 2023

dlegge Sun, 21/01/2024 - 12:06

HAI

IPRs and Access in Emergencies

The World Health Organization declaration that “the global health emergency of COVID-19 is over” has removed the sense of urgency that for more than three years shaped global health discussions.1 As a result of the pandemic, the topic of intellectual property (IP) and its influence on access to health technologies was widely and intensely discussed. The support gathered by a waiver proposal on certain parts of the Trade Related aspects of Intellectual Property (TRIPS) Agreement, the creation of the COVID-19 Technologies Access Pool (C-TAP) and a number of national and regional initiatives aimed at scaling up production of health goods are just some examples of where the needs of the many were framed above pro昀椀ts and monopolies. Several policy processes that were set-aside, stalled or even stopped during the pandemic have resumed, while initiatives that originated in the response to the pandemic have either evolved or run their course. This policy brief looks at some of the interventions designed during the COVID-19 pandemic to counter the impact of excessive use of IP protection tools. Secondly, it assesses recent post-pandemic policy discussions, at every level, regarding the role of IP in relation to access to innovation. Finally, it sets out several recommendations on the management of IP and related policy processes in order to improve access to health technologies. THE TRIPS WAIVER The TRIPS waiver proposal submitted by India and South Africa in October 2021, in the midst of deadly pandemic for which, at the time, there was no proven treatment, placed the relationship between IP and access to health technologies at the top of the global health agenda.2

Keywords

IPRs